- Conditions
- Alzheimer's Disease
- Interventions
- LY450139 dihydrate, placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 6
- States / cities
- La Jolla, California • Indianapolis, Indiana • St Louis, Missouri + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 17,105
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cold Agglutinin Disease
- Interventions
- sutimlimab (BIVV009), placebo
- Drug
- Lead sponsor
- Bioverativ, a Sanofi company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Los Angeles, California • Georgetown, District of Columbia + 10 more
- Conditions
- Short Bowel Syndrome
- Interventions
- Pancreatic Enzyme
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 4 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
- Interventions
- Not listed
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 2,981 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2031
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 10 more
- Conditions
- FAP, Familial Amyloid Polyneuropathy, TTR, Transthyretin, Amyloidosis
- Interventions
- Inotersen, Placebo
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 82 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 9
- States / cities
- Orange, California • Indianapolis, Indiana • Baltimore, Maryland + 5 more
- Conditions
- Depression, Hypertension
- Interventions
- Collaborations in Health (COACH)
- Behavioral
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 2,685 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 4
- States / cities
- New Orleans, Louisiana • Ann Arbor, Michigan • Rochester, New York + 1 more
- Conditions
- Seborrheic Dermatitis
- Interventions
- Test Product 49778, Test Product 10156, Vehicle (placebo)
- Drug
- Lead sponsor
- Medicis Global Service Corporation
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 22
- States / cities
- Fremont, California • Los Angeles, California • San Diego, California + 19 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Ivonescimab Injection, Pembrolizumab Injection
- Biological
- Lead sponsor
- Summit Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 780 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 97
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 86 more
- Conditions
- Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia, Refractory
- Interventions
- CART123 cells; cyclophosphamide; fludarabine
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 1 Year to 29 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Endometrial Cancer
- Interventions
- docetaxel
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 63 more
- Conditions
- Sleep Apnea, Obstructive, Hypertension
- Interventions
- Positive Airway Pressure
- Device
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Malignant Ovarian Mixed Epithelial Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Undifferentiated Ovarian Carcinoma
- Interventions
- Carboplatin, Cyclophosphamide, Filgrastim, Paclitaxel, Peripheral Blood Stem Cell Transplantation, Topotecan Hydrochloride
- Drug · Biological · Procedure
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Arthritis, Rheumatoid
- Interventions
- celecoxib, Ibuprofen, Naproxen
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24,081 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 871
- States / cities
- Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 515 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Itacitinib, Pembrolizumab
- Drug · Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Prostate Cancer Early Risk Treated by Radiosurgery, Prostate Cancer Intermediate Risk Treated by Radiosurgery
- Interventions
- Not listed
- Lead sponsor
- RPCR, Inc.
- Other
- Eligibility
- 18 Years to 90 Years · Male only
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 39 more
- Conditions
- Chronic Pancreatitis
- Interventions
- Creon36™
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lymphoma
- Interventions
- filgrastim, gemcitabine hydrochloride, vinorelbine tartrate
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 108
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 93 more
- Conditions
- Chronic Kidney Disease, Proteinuria, Children
- Interventions
- Finerenone (Kerendia, BAY94-8862)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 15 more
- Conditions
- Metastatic Melanoma
- Interventions
- Obatoclax Mesylate, Temozolomide
- Drug
- Lead sponsor
- Gemin X
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Endometrial Cancer
- Interventions
- alvocidib
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 42 more
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- Nivolumab, Ipilimumab, Pemetrexed, Cisplatin, Carboplatin
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 18
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 12 more
- Conditions
- Alpha 1-Antitrypsin Deficiency, Emphysema
- Interventions
- SAR447537, Zemaira
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
- Conditions
- Inhibitory Control Training, Gameifaction
- Interventions
- No-Added-Sugar Diet
- Behavioral
- Lead sponsor
- Drexel University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pancreatic Neoplasms, Solid Tumors, Biliary Tract Cancer, Lung Neoplasms, Bladder Cancer
- Interventions
- Brigimadlin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 18
- States / cities
- Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 14 more